[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562822":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":29,"collaborators":7,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":7,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":7,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"countryCode":16,"cosmosGeoPoint":17,"geoPoint":22,"contacts":23},"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","RECRUITING","Shanghai","Shanghai Municipality","200000","China","CN",{"type":18,"coordinates":19},"Point",[20,21],121.45806,31.22222,{"lat":21,"lon":20},[24],{"name":25,"role":26,"phone":27,"phoneExt":7,"email":28},"yi xiang","CONTACT","13816967846","xiangyiht@163.com",{"type":30,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100562822","68ga-grazytracer-pet-assists-in-diagnosing-pseudoprogression-following-immunotherapy-in-lung-cancer-100562822",false,"NCT06608160","68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.","68Ga-grazytracer PET\u002FCT Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer: a Prospective, Observational Study.","Inclusion Criteria:\n\n1. Lung cancer patients who develope lesion enlargement and\u002For new lesions after treatment with immune checkpoint inhibitors;\n2. Pseudoprogression cannot be ruled out in clinical practice;\n3. Lung cancer confirmed by pathology or cytology, regardless of pathological type;\n4. Fully-informed written consent obtained from patients;\n5. Patient ability to comply with protocol requirements;\n6. Age 18-75 years;\n7. Life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n1. Patients with serious diseases that the investigator deems unsuitable for participation in the clinical study. Such as severe cardiopulmonary insufficiency, severe bone marrow suppression, severe hepatic or renal insufficiency, etc;\n2. Intestinal perforation, complete intestinal obstruction;\n3. Active phase of hepatitis B；\n4. Pregnant women and women who are potentially pregnant, as well as nursing mothers;\n5. Patients with poor compliance.","ALL","18 Years","75 Years",{"count":42,"type":43},30,"ESTIMATED","OBSERVATIONAL","Currently, there are limited methods available in clinical practice to distinguish pseudoprogression after immunotherapy. Most patients rely on follow-up observations to monitor the disease, which does not meet clinical needs. 68Ga-grazytracer is a novel imaging agent targeting granzyme B. By detecting the concentration of granzyme B, it reflects the localization of cytotoxic T cells in the tumor region and their potential ability to kill tumor cells. This study aims to leverage the simplicity, non-invasiveness, visualization, and semi-quantitative advantages of 68Ga-grazytracer PET imaging to evaluate its effectiveness and feasibility in diagnosing pseudoprogression.",[47,48,49],"PET \u002F CT","Lung Carcinoma","Immunotherapy","2024-09-19",{"date":52,"type":53},"2024-09-23","ACTUAL",{"date":55,"type":53},"2024-06-20",{"date":57,"type":43},"2025-12-31",{"name":5,"class":6},1]